Evommune, Inc.
About Evommune, Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $13.0M
- Net income
- -$68.9M
- Total assets
- $224.9M
- Market cap
- $717.5M
- Operating margin
- -623.6%
- Net margin
- -529.8%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $13.0M
- Operating expenses
- $94.1M
- Operating income
- -$81.1M
- Income tax
- $0
- Net income
- -$68.9M
- EPS (basic)
- $-11.22
- EPS (diluted)
- $-11.22
Balance sheet
- Total assets
- $224.9M
- Current assets
- $153.5M
- Total liabilities
- $19.4M
- Current liabilities
- $17.9M
- Shareholders’ equity
- $205.6M
Cash flow
- Operating cash flow
- -$76.4M
- Investing cash flow
- -$115.3M
- Financing cash flow
- $220.8M
- Net cash flow
- $29.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $717.5M
- EPS (diluted)
- $-11.22
- Shares outstanding
- 35.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $68.9M in FY2025.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Evommune, Inc..
